Phase 2
N=3
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Bottom Line
View on ClinicalTrials.gov: NCT02354781 ↗Enrolled (actual)
3
Serious AEs
33.3%
Results posted
Apr 2020
Primary outcome: Primary: Number of Dose Limiting Toxicity (DLT) Adverse Events as Assessed by 21 CFR 312.32. — 0 Number of Events
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- rAAV1.CMV.huFollistin344 (Biological)
- Age
- Pediatric, Adult, Older Adult · 7+ yrs
- Sex
- Male
- Sponsor
- Jerry R. Mendell
- Primary completion
- Nov 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Dose Limiting Toxicity (DLT) Adverse Events as Assessed by 21 CFR 312.32. |
— | — |
| SECONDARY Muscle Function Measured by Six-minute Walk Test (6MWT) |
— | — |
| SECONDARY Expression of Viral DNA (qPCR), and Follistatin Transgene in Muscle Tissue |
— | — |
| SECONDARY Improvement of Muscle Function as Measured by North Star Ambulatory Assessment (NSAA) |
1 | — |
Summary
The proposed clinical trial is an outgrowth of the safety record and functional improvement seen in the BMD follistatin gene therapy trial. In this study the investigators propose to inject AAV1.CMV.huFS344 at a total dose of 2.4E12 vg/kg to six DMD patients. This dose will be divided between gluteal muscles, quadriceps and tibialis anterior. This is a wider distribution of vector than given to BMD patients, who overall improved the distance walked on the 6MWT without adverse events related to viral transduction into a single muscle.
Eligibility Criteria
Inclusion Criteria
- Age 7 or older
- Confirmed DMD gene mutations
- Impaired muscle function based on clinical evidence including difficulty climbing stairs, getting from the floor (Gowers' sign), and weakness of individual muscles of extremities
- Males of any ethnic group will be eligible
- Ability to cooperate with study procedures including muscle testing.
- Willingness of sexually active subjects with reproductive capacity to practice reliable method of contraception
- Subjects must be on stable dose of prednisone for three months at time of enrollment or be started on oral dose of daily prednisone regimen for 30 days prior to gene transfer. Study participants will continue prednisone post gene transfer unless there is adverse event that warrants prednisone taper or withdrawal.
Exclusion Criteria
- Active viral infection based on clinical observations.
- The presence of a DMD gene mutation without weakness or loss of function
- Symptoms or signs of cardiomyopathy, including:
- Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs
- Echocardiogram with ejection fraction below 40%
- Serological evidence of HIV infection, or Hepatitis A, B or C infection
- Diagnosis of (or ongoing treatment for) an autoimmune disease
- Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer
- Subjects with rAAV1 binding antibody titers > 1:50 as determined by ELISA immunoassay
- Abnormal laboratory values for liver, kidney, CBC, in the clinically significant range, based upon normal values in the Nationwide Children's Hospital Laboratory
Data sourced from ClinicalTrials.gov (NCT02354781). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.